Teva Recalls Almost 800,000 Inhalers for Irregularity

Teva Pharmaceutical Industries Ltd. is recalling 792,603 asthma inhalers because they failed tests to ensure they had identical contents.

The recall began Nov. 23 and affects prescription ProAir HFA inhalers sold nationwide, the U.S. Food and Drug Administration said in a notice available on its website today.

Respiratory products accounted for $898 million, or 6.5 percent, of Teva’s revenue in 2009. The Petah Tikva, Israel- based company, the world’s largest maker of generic drugs, said the irregularities with the four batches of ProAir HFA have no impact on patients. Three of the lots have expired and one expires this month.

“We continue to work through our investigation and are keeping FDA informed of our findings,” Denise Bradley, a U.S. spokeswoman for Teva, said today in an e-mail.

To contact the reporter on this story: Catherine Larkin in Washington at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.